Results 41 to 50 of about 14,471,607 (152)

The Malaysian Society of Gastroenterology and Hepatology Consensus Statements on Prevention and Early Detection of Hepatocellular Carcinoma in Malaysia

Journal of Gastroenterology and Hepatology, Volume 41, Issue 9, Page 2639-2655, September 2026.
ABSTRACT Background Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer‐related deaths in Malaysia. Early detection increases the likelihood of curative treatment and improves survival. This consensus document aims to provide evidence‐based, locally relevant recommendations for the prevention and early detection of HCC.
Su Yin Lau, Victoria Sinq‐Ling Kok, Soek‐Siam Tan, Syuhada Dan Adnan, Wei‐Lin Ng, Ban‐Hong Ang, Nur Yazmin Yaacob, Yeong Yeh Lee, Senamjit Kaur, Rosmawati Mohamed, Ping‐Foo Wong, Lee‐Ling Lim, Mohana Letchumanan, Shireene Ratna Vethakkan, Nurain Mohd Noor, Siow‐Foon Tan, Tiong‐Lim Low, Lee‐Boon Kiew, Wah‐Kheong Chan   +18 more
wiley   +1 more source

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Hepatology Research, Volume 56, Issue 7, Page 1170-1176, July 2026.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Atsushi Masamune   +8 more
wiley   +1 more source

Prediction of Invasive Activities in Hepatocellular Carcinomas with Special Reference to  -Fetoprotein and Des- -carboxyprothrombin [PDF]

Japanese Journal of Clinical Oncology, 2003
Hepatocellular carcinoma (HCC) is one of the world's major malignancies, especially in Asian countries. To improve the prognosis of HCC, it is essential to predict its invasive behavior in both intra- and extra-hepatic modalities. For this purpose, we examined the predictive values of two tumor markers, alpha-fetoprotein (AFP) and des-gamma ...
Miki, Gotoh, Tomohiro, Nakatani, Taizo, Masuda, Yasunori, Mizuguchi, Michiie, Sakamoto, Ryosuke, Tsuchiya, Hoichi, Kato, Koh, Furuta   +7 more
openaire   +2 more sources

KETIDAKSAMAAN PADA FUNGSI Q-GAMMA

, 2012
Alsina and Tomas (2005) discuss about inequaty of the gamma function by geometricalapproach. Sandor (2005) and Baiduri (2008) discuss about some inequalities that involves the gammafunction based on the series representaion of psi function.
., Baiduri
core   +1 more source

Long-Term Prognostic Value of AFP and PIVKA-II in HCC After Living Donor Liver Transplantation: A Single-Center Retrospective Study

Transplant International
Despite the development of numerous prognostic models for hepatocellular carcinoma (HCC) recurrence and mortality after liver transplantation, tumor biomarkers such as alpha-fetoprotein (AFP) and protein induced by vitamin K absence-II (PIVKA-II) remain ...
Saran Ochir Gongor, YoungRok Choi, YoungRok Choi, Gayoung Kim, Min Kyoung Kim, Sang Hyuk Park, Jiyoung Kim, Jae-Yoon Kim, Jae-Yoon Kim, Su young Hong, Jeong-Moo Lee, Suk Kyun Hong, Suk Kyun Hong, Kwang-Woong Lee, Kwang-Woong Lee   +14 more
doaj   +1 more source

Enterococcus faecalis Extracellular Vesicles Deliver the Bacterial GTPase Obg to Hijack mTOR Signalling in Hepatocellular Carcinoma

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
E. faecalis is enriched in HCC tissue and can promote liver tumourigenesis by activating mTOR signalling pathway. Obg derived from E. faecalis extracellular vesicles (EVs) is a GTPase physically interacts with mTOR, and acts as an interkingdom activator of mTOR. EF‐Obg expression level in HCC tissue correlates with poor prognosis in HCC patients.
Ning Ma, Xiaoshan Xie, Jiarui Wang, Zhikai Zheng, Huilin Jin, Xijie Chen, Xiaoling Huang, Haidan Luo, Yue Wei, Qihao Pan, Boyu Zhang, Jiaying Zheng, Peng Zhang, Fenghai Yu, Xue Liu, Zhi‐Min Zhang, Zhongguo Zhou, Xiangqi Meng, Mong‐Hong Lee   +18 more
wiley   +1 more source

Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Durvalumab plus tremelimumab (Dur/Tre) is the first‐line treatment for unresectable hepatocellular carcinoma (uHCC). Immune‐mediated adverse events (imAEs) are common; however, the impact of specific imAE types on treatment persistence and outcomes remains unclear.
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yoshihide Ueda, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, on behalf of the RELPEC Group and HCC 48 Group   +53 more
wiley   +1 more source

Comparison of Anatomical and Non‐Anatomical Resection in Low Microvascular Invasion Risk Solitary Hepatocellular Carcinoma ≤ 5 cm

Annals of Gastroenterological Surgery, Volume 10, Issue 3, Page 861-870, May 2026.
We evaluated whether anatomical resection (AR) provides an oncological benefit over non‐anatomical resection (NAR) in solitary hepatocellular carcinoma ≤ 5 cm without predicted microvascular invasion or intrahepatic metastasis, identified by preoperative DCP ≤ 150 mAU/mL.
Norifumi Iseda, Shinji Itoh, Kyohei Yugawa, Shohei Yoshiya, Takashi Motomura, Takeo Toshima, Tomoharu Yoshizumi   +6 more
wiley   +1 more source

Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Chinese Retrospective Multicenter Study Based on Global Meta‐Analysis

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Objective Microvascular invasion (MVI) has been identified as a risk factor for the prognosis of patients with hepatocellular carcinoma (HCC). However, it can only be diagnosed pathologically, and thus no widely applicable preoperative MVI risk prediction model has been established.
Jia Xu, Yue‐Lu Zhang, Man Yang, Zhengbo Deng, Laisheng Li, Ting Wang, Jinhua Song, Hai Xu, Jian Wu, Zhi‐Qi Wu, Hua‐Guo Xu   +10 more
wiley   +1 more source

Cover Jurnal Gamma, Vol. 7, No.2, Maret 2012

, 2014
Cover Jurnal Gamma, Vol.
., Cover
core   +1 more source